Clinical Trials Logo

Clinical Trial Summary

Based on the investigator's previous data on risk classification for acute leukemia,the investigators will design a set of panels to detect the gene expression and genomic variants (SNPs, mutation, insertion, deletion and fusion genes, etc), and identify the high-risk subtypes of acute leukemia, such as Ph-like acute lymphoblastic leukemia. Furthermore, the target therapy (Tyrosine Kinase Inhibitors,et.al) will be used to treat the identified patients. In addition, more sensitive minimal residual disease (MRD) detection technology will be designed and used to detect the MRD in patients to early predict the disease relapse.


Clinical Trial Description

patient eligibility criteria: newly diagnosed acute leukemia patients with clinical high-risk markers, reflactory and relapsed patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03297476
Study type Observational
Source Zhongda Hospital
Contact
Status Completed
Phase
Start date December 1, 2017
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03680677 - Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Completed NCT04194086 - Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia Phase 1/Phase 2
Completed NCT04710212 - Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
Terminated NCT01050764 - Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells Phase 1/Phase 2
Completed NCT03434704 - Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole Phase 2
Recruiting NCT05823571 - Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Phase 1
Completed NCT04236063 - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Completed NCT04745416 - Clinical Characteristics of Patients With Leukemia and COVID-19
Not yet recruiting NCT03336632 - Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT Phase 2
Completed NCT05969600 - The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3
Recruiting NCT06335277 - Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology
Recruiting NCT03564704 - Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL Phase 2/Phase 3
Recruiting NCT03553238 - Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL Phase 2/Phase 3
Recruiting NCT03564470 - Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL Phase 2/Phase 3
Terminated NCT03963024 - Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT Phase 1
Completed NCT04051216 - The SMART CART Study: Health Information Technology N/A
Recruiting NCT04482894 - Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS Phase 2
Recruiting NCT05236296 - Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) Pilot Study N/A